Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPDI65
|
|||
| Drug Name |
Dazodalibep
|
|||
| Synonyms |
VIB4920
Click to Show/Hide
|
|||
| Indication | Kidney transplant rejection [ICD-11: NE84; ICD-9: 996.81] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 2 | [2] | ||
| Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0; ICD-9: 710.2] | Phase 2 | [3] | ||
| Company |
HORIZON
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04046549) A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04163991) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA). U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT04129164) A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sj?gren's Syndrome (SS). U.S.National Institutes of Health. | |||
| REF 4 | The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.